UBS Group’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2021
Q4 | – | Sell |
-1,355
| Closed | -$24K | – | 9969 |
|
2021
Q3 | $24K | Sell |
1,355
-1,264,467
| -100% | -$22.4M | ﹤0.01% | 5869 |
|
2021
Q2 | $12.3M | Sell |
1,265,822
-56,762
| -4% | -$551K | ﹤0.01% | 1377 |
|
2021
Q1 | $14.2M | Buy |
1,322,584
+577,954
| +78% | +$6.21M | ﹤0.01% | 1239 |
|
2020
Q4 | $11M | Buy |
744,630
+743,813
| +91,042% | +$10.9M | ﹤0.01% | 1338 |
|
2020
Q3 | $12K | Sell |
817
-4,483
| -85% | -$65.8K | ﹤0.01% | 5856 |
|
2020
Q2 | $43K | Sell |
5,300
-6,013
| -53% | -$48.8K | ﹤0.01% | 5164 |
|
2020
Q1 | $46K | Buy |
+11,313
| New | +$46K | ﹤0.01% | 5020 |
|
2019
Q4 | – | Sell |
-29,208
| Closed | -$9K | – | 7318 |
|
2019
Q3 | $9K | Buy |
29,208
+14,143
| +94% | +$4.36K | ﹤0.01% | 6274 |
|
2019
Q2 | $5K | Sell |
15,065
-1,441
| -9% | -$478 | ﹤0.01% | 6534 |
|
2019
Q1 | $11K | Buy |
16,506
+11,040
| +202% | +$7.36K | ﹤0.01% | 5944 |
|
2018
Q4 | $9K | Buy |
5,466
+2,957
| +118% | +$4.87K | ﹤0.01% | 6383 |
|
2018
Q3 | $15K | Buy |
2,509
+1,706
| +212% | +$10.2K | ﹤0.01% | 6057 |
|
2018
Q2 | $5K | Buy |
803
+322
| +67% | +$2.01K | ﹤0.01% | 6567 |
|
2018
Q1 | $3K | Buy |
+481
| New | +$3K | ﹤0.01% | 6568 |
|
2017
Q4 | – | Sell |
-1,230
| Closed | -$6K | – | 7068 |
|
2017
Q3 | $6K | Buy |
+1,230
| New | +$6K | ﹤0.01% | 6251 |
|
2017
Q2 | – | Sell |
-1,997
| Closed | -$12K | – | 6965 |
|
2017
Q1 | $12K | Buy |
1,997
+720
| +56% | +$4.33K | ﹤0.01% | 5598 |
|
2016
Q4 | $7K | Buy |
1,277
+1,077
| +539% | +$5.9K | ﹤0.01% | 6141 |
|
2016
Q3 | $3K | Buy |
200
+34
| +20% | +$510 | ﹤0.01% | 6386 |
|
2016
Q2 | $1K | Buy |
+166
| New | +$1K | ﹤0.01% | 6664 |
|
2016
Q1 | – | Sell |
-2,014
| Closed | -$25K | – | 6969 |
|
2015
Q4 | $25K | Buy |
2,014
+889
| +79% | +$11K | ﹤0.01% | 5374 |
|
2015
Q3 | $15K | Buy |
+1,125
| New | +$15K | ﹤0.01% | 5683 |
|